TNF inhibitors, such as adalimumab (ADA) and etanercept (ETA), and other classes of biological therapies, including IL-6 inhibitors like tocilizumab (TCZ), CTLA-4 inhibitors like abatacept (ABA), and anti-CD20 agents like rituximab (RTX), have been shown to significantly improve the quality of life and symptoms in RA patients (Gerhold et al., 2015). Here, TNF is linked to rheumatoid arthritis.